Now Comes The Hard Part: Sandoz Must Sell Its Biosimilar
This article was originally published in The Pink Sheet Daily
Executive Summary
After developing a seemingly ideal application and winning a history-making approval, Sandoz still faces a patent case, and then it would enter territory where it has stumbled before: pricing and marketing a complex product in a crowded market.
You may also be interested in...
Biosimilar Pricing: Sandoz Vows Not To Make Omnitrope ‘Mistake’ With Filgrastim
Sandoz, Hospira execs say U.S. payers and consumers will ‘not be disappointed’ in cost savings from products approved under the 351(k) pathway, but warn that price alone may not tell whole story.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.